Soooooo, imafusspot is a subsidiary of a subsidiary of a company that CGB picked up during the "Company Transformation".
The revenues from imafusspot, Vitahemp, EM Wholefoods, T12 are IMO, what is being reported on as earnings.
Medcan eventually pulled out of the deal and was not purchased (via share allocations).
Medcan Australia was granted the 13th Cultivation and Production licence from the Office of Drug Control in November 2017 with a nominated commencement start date for production being the 1st of July 2018.
CGB Price at posting:
2.9¢ Sentiment: None Disclosure: Held